A Startup Has Unlocked a Way to Make Cheap Insulin
Now some key patents have expired, and the US Food and Drug Administration has paved the way for biosimilar versions of insulin—so-called because they’re almost identical to another product already on the market. For a product to be biosimilar, it must be highly similar in structure to the original and work just as well in … Read more
